COVID-19, and more rarely the mRNA-based COVID-19 vaccine, can lead to inflammation of heart tissue in some individuals. A ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

A team led by Rensselaer Polytechnic Institute (RPI) professors Georges Belfort, Ph.D. (PI), and Pankaj Karande, Ph.D. (co-PI ...

GC Biopharma (006280.KS), a leading global biopharmaceutical company, announced today that Ministry of Food and Drug Safety (MFDS) in South Korea has approved the Investigational New Drug (IND) ...

MIT and Broad Institute researchers have developed an mRNA approach that temporarily programs liver cells to produce ...

RNA vaccines, such as those used against COVID-19, are effective at generating antibody responses. These antibodies are ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

New data highlight liver-encoded delivery of immune modulators as a strategy to mitigate age-related immune dysfunction.

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

As people age, their immune system function declines. T cell populations become smaller and can't react to pathogens as ...

As the immune system weakens with age, researchers have found a way to temporarily boost its function by reprogramming liver cells to support T-cell development.

A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...